## **Core Concept**
The question tests knowledge of opportunistic infections in immunocompromised patients, specifically those with HIV/AIDS, and the identification of pathogens based on microscopic characteristics. The patient's severe pneumonia and the presence of cup-shaped cysts with sharply outlined walls in the lower respiratory tract secretions are key to identifying the causative organism.

## **Why the Correct Answer is Right**
The description of "cup-shaped cysts with sharply outlined walls" in the context of a severe pneumonia in an HIV-positive patient is highly suggestive of *Pneumocystis jirovecii* (formerly known as *Pneumocystis carinii*). This organism is a common cause of opportunistic infections in immunocompromised individuals, particularly those with HIV/AIDS. The methenamine silver stain is a specific staining technique used to visualize the cysts of *Pneumocystis jirovecii*. The characteristic morphology and the clinical context make *Pneumocystis jirovecii* the most likely pathogen.

## **Why Each Wrong Option is Incorrect**
- **Option A:** *Cryptococcus neoformans* is a type of encapsulated yeast that can cause infections in immunocompromised patients, particularly those with HIV/AIDS. However, it does not produce cup-shaped cysts and is typically identified by its encapsulated yeast cells in India ink stain, not methenamine silver stain.
- **Option B:** *Histoplasma capsulatum* is a dimorphic fungus that causes histoplasmosis. It is identified by its small, intracellular yeast cells, not cup-shaped cysts, and is more commonly associated with exposure to bird or bat droppings.
- **Option D:** *Toxoplasma gondii* is a protozoan that can cause toxoplasmosis in immunocompromised patients. However, it does not present as cup-shaped cysts in respiratory secretions and is typically identified through serological tests or direct detection of the tachyzoites or cysts in tissues.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that *Pneumocystis jirovecii* pneumonia (PCP) is a leading cause of morbidity and mortality in HIV-infected individuals with a CD4 count below 200 cells/μL. The first-line treatment for PCP is trimethoprim-sulfamethoxazole (TMP-SMX). Prophylaxis against PCP is recommended for HIV-infected patients with CD4 counts below 200 cells/μL.

## **Correct Answer:** .